ASTRAGALOSIDE A

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C41H68O14
Molecular Weight	784.9702
Optical Activity	UNSPECIFIED
Defined Stereocenters	21 / 21
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)(O)[C@H]1CC[C@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H]6[C@]7(C[C@@]47CC[C@]23C)CC[C@H](O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O)C6(C)C

InChI

InChIKey=QMNWISYXSJWHRY-AUJDEUPOSA-N

InChI=1S/C41H68O14/c1-35(2)24(54-33-29(48)26(45)20(44)17-51-33)9-11-41-18-40(41)13-12-37(5)31(39(7)10-8-25(55-39)36(3,4)50)19(43)15-38(37,6)23(40)14-21(32(35)41)52-34-30(49)28(47)27(46)22(16-42)53-34/h19-34,42-50H,8-18H2,1-7H3/t19-,20+,21-,22+,23-,24-,25+,26-,27+,28-,29+,30+,31-,32-,33-,34+,37+,38-,39-,40-,41+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C41H68O14
Molecular Weight	784.9702
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	21 / 21
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16450288 | https://www.ncbi.nlm.nih.gov/pubmed/24024343 | https://www.ncbi.nlm.nih.gov/pubmed/27567103

Astragaloside A (Astragaloside IV) is the primary pure saponin isolated from Astragalus membranaceus, which has been widely used for the treatment of cardiovascular diseases. Astragaloside IV improves post-ischemic heart function and ameliorated reperfusion arrhythmias accompanied by a significant increase in myocardial antioxidative enzyme superoxide dismutase activity in rat hearts in vitro. While, Astragaloside IV's protective effect on heart function can be partially abrogated by the nitric oxide synthase inhibitor, Nomega-nitro-L-arginine methyl ester. Astrageloside IV has multiple pharmacologic effects, including anti-inflammatory, antifibrotic, antioxidative stress, anti-asthma, antidiabetes, immunoregulation, and cardioprotective effect via numerous signaling pathways. According to the existing studies and clinical practices, Astragaloside A possesses potential for broad application in many diseases.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Oxidative Stress 162 Target ID: WP408 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24124567	Inhibitor 8504
Transient receptor potential cation channel subfamily M member 7 6 Target ID: Q925B3 Gene ID: NA Gene Symbol: Trpm7 Target Organism: Rattus norvegicus (Rat) Sources: https://www.ncbi.nlm.nih.gov/pubmed/28545665	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Multiple sclerosis 107 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24124567	Primary	Preclinical	Unknown Approved Use Unknown
Intracranial arterial stenosis 1 Sources: https://clinicaltrials.gov/ct2/show/NCT01553643	Primary	Phase IV 63	Unknown Approved Use Unknown
Lung cancer 70 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27960166	Primary	Preclinical	Unknown Approved Use Unknown
Myocardial ischemia 14 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16450288 https://www.ncbi.nlm.nih.gov/pubmed/17509559	Primary	Preclinical	Unknown Approved Use Unknown
Cardiac fibrosis 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28545665	Primary	Preclinical	Unknown Approved Use Unknown
Acute liver failure 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27938564	Primary	Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Astragaloside IV ameliorates acute pancreatitis in rats by inhibiting the activation of nuclear factor-κB.	2015-03	25604657
Effects of Astragaloside IV combined with the active components of Panax notoginseng on oxidative stress injury and nuclear factor-erythroid 2-related factor 2/heme oxygenase-1 signaling pathway after cerebral ischemia-reperfusion in mice.	2014-10	25422538
Modification of alterations in cardiac function and sarcoplasmic reticulum by astragaloside IV in myocardial injury in vivo.	2007-07-30	17509559

Patents

Sample Use Guides

In Vivo Use Guide

Astragaloside A (5 and 10 mg/kg/day, intraperitoneal injection) reduced serum lactate dehydrogenase and creatine kinase enzyme levels and attenuated this reduction in the Ca2+-ATPase activity in rats

Route of Administration: Intraperitoneal

In Vitro Use Guide

Astragaloside A (Astragaloside IV) (2-40 uM) dose-dependently decreased TGF-β-induced a-SMA, fibronectin, CTGF, collagen I and III expression, up-regulated Smad7, but decreased p-Smad2 and p-Smad3 expression in NRK-49F cells.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:37:44 GMT 2025` Edited by `admin` on `Mon Mar 31 21:37:44 GMT 2025`
Record UNII	3A592W8XKE
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

(+)-ASTRAGALOSIDE A

Preferred Name

English

ASTRAGALOSIDE A

Common Name

English

ASTRAGALIN A

Common Name

English

ASTRAGALOSIDE-A

Common Name

English

.BETA.-D-GLUCOPYRANOSIDE, (3.BETA.,6.ALPHA.,16.BETA.,24R)-20,24-EPOXY-16,25-DIHYDROXY-3-(.BETA.-D-XYLOPYRANOSYLOXY)-9,19-CYCLOLANOSTAN-6-YL-

Common Name

English

CYCLOSIVERSIOSIDE F

Common Name

English

ASTRAMEMBRANNIN I

Common Name

English

Code System Code Type Description

CHEBI

65457